Triple-negative breast cancer (TNBC) refers to a distinct subclass of breast cancer with the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, making it a clinically challenging subtype with fewer therapeutic pathways. This evidence concerns the gene ERBB2 and breast carcinoma.